Eisai Co., Ltd. Annual Report 2014
Annual Report
-------------
To Our Stakeholders
Eisai’s Main Products and Investigational Compounds
Results for the Fiscal Year Ended March 2014
Consolidated Financial Highlights
Segment Information
Corporate Philosophy
Eisai’s Value Creation Process and Flow (Editorial Policy)
External Business Environment and Strategy
Adoption of Global Business Matrix Structure in Response to Change in Global Business Climate
Shift from Two-Brand Company to Multi-Brand Company
Eisai’s Unique Business Models
Aricept®
Halaven®
BELVIQ®
Measures to Improve Access to Medicines—Price Zero*1 Provision of DEC Tablets
Eisai’s Six Types of Capital
Intellectual Capital
R&D System
Pipeline
Neurology Field Major R&D Pipeline
Fycompa®
Developing a Next-Generation Alzheimer’s Disease Treatment
Oncology Field Major R&D Pipeline
Lenvatinib (Generic Name)
Vascular and Immunological Reaction
Gastrointestinal and Hepatic Disorders
Open Innovation and Advanced Technologies
Protection and Reinforcement of Intellectual Property
Manufactured Capital
Production System (Demand Chain)
Human Capital
Global Marketing System
Employees
Social and Relationship Capital
Eisai’s Partnership Initiatives
Activities for Corporate Social Responsibility
Natural Capital
Business with Consideration for the Global Environment
Financial Capital
Financial Strategy
ROE Management
Shareholder Returns
Status of Shares
Corporate Governance
Corporate Governance System
Outside Director Interview
Board of Directors and Executive Officers
Compliance & Risk Management
Risk Factors
Corporate Information
Japan and Overseas Operations
Corporate Data
Page
of
Save this page
My favorite pages
Download center
Send to a friend
Help
Iframe content
Page
of
Powered by ©
Euroland.com
Page saved
Page already saved
Page deleted
No saved pages